Front Cover -- The Alkaloids Chemistry and Biology -- The Alkaloids Chemistry and Biology -- Contents -- CONTRIBUTORS -- PREFACE -- One -- Acridone Alkaloids -- 1. INTRODUCTION -- 2. BIOSYNTHESIS -- 3. OCCURRENCE AND CHARACTERIZATION -- 3.1 Simple Acridone Alkaloids -- 3.2 C-Prenyl Acridone Alkaloids -- 3.3 Furoacridone Alkaloids -- 3.4 Pyranoacridone Alkaloids -- 3.5 Dimeric Acridone Alkaloids and Related Compounds -- 3.6 Miscellaneous Alkaloids -- 4. SYNTHESIS -- 4.1 Simple Acridone Alkaloids -- 4.1.1 Methods Involving the Cyclization of Diarylamine Intermediates -- 4.1.2 Methods Involving the Cyclization of Benzophenone Intermediates -- 4.1.3 Other Methods -- 4.2 C-Prenyl Acridone Alkaloids -- 4.3 Furoacridone Alkaloids -- 4.4 Pyranoacridone Alkaloids -- 4.5 Azacridone-A -- 4.6 Acrimarines -- 5. BIOLOGICAL PROPERTIES -- 5.1 Cytotoxicity and Anticancer Activity -- 5.2 Antimicrobial Activity -- 5.3 Antiparasitic Activity -- 5.4 Enzyme Inhibition -- 5.5 Other Biological Effects -- 5.6 Biologically Active Synthetic Analogs of Acridone Alkaloids -- ACKNOWLEDGMENTS -- REFERENCES -- Two -- Galbulimima Alkaloids -- 1. INTRODUCTION -- 2. ISOLATION AND CLASSIFICATION -- 3. BIOLOGICAL PROPERTIES -- 4. BIOSYNTHESIS -- 5. SYNTHESIS OF GALBULIMIMA ALKALOIDS -- 5.1 Synthesis of Class I Galbulimima Alkaloids -- 5.2 Synthesis of Class II Galbulimima Alkaloids -- 5.3 Synthesis of Class III Galbulimima Alkaloids -- 5.4 Synthesis of Class IV Galbulimima Alkaloids (Miscellaneous Alkaloids) -- 6. CONCLUSION -- REFERENCES -- Three -- Total Synthesis of Lundurine and Related Alkaloids: Synthetic Approaches and Strategies -- 1. BACKGROUND -- 2. SYNTHETIC APPROACHES -- 2.1 Basic Strategies -- 2.2 Synthesis of Azocine-Fused Indoles and Indolines -- 2.3 Synthesis of Functionalized Cyclopropa[b]indole Core -- 3. TOTAL SYNTHESIS OF LUNDURINES A AND B BY NISHIDA4-6.

3.1 First Synthesis of Lundurine B4 -- 3.1.1 Retrosynthetic Analysis of Lundurine B -- 3.1.2 Model Study30 -- 3.1.3 Total Synthesis of (±)-Lundurine B4 -- 3.1.4 Unexpected Reactions Observed During Model Studies and Total Synthesis30 -- 3.2 Concise Synthesis of (±)-Lundurines A and B5 -- 3.3 Synthesis of (−)-Lundurine B6 -- 4. SYNTHESIS OF (−)-LUNDURINE A BY QIN9,10 -- 5. SYNTHESIS OF (−)-LUNDURINES A-C BY ECHAVARREN11 -- 6. SYNTHESIS OF OTHER RELATED ALKALOIDS: (+)-LAPIDILECTINE B AND (+)-GRANDILODINE C54 -- 7. CONCLUSION -- REFERENCES -- Four -- Cephalotaxus Alkaloids -- 1. INTRODUCTION -- 2. NATURAL OCCURRENCE, ISOLATION, AND STRUCTURAL ASSIGNMENT -- 2.1 Cephalotaxine and Related Alkaloids -- 2.2 Natural Cephalotaxus Esters -- 2.3 Other Alkaloids -- 2.4 Production and Purification Studies -- 3. SYNTHESIS OF THE ALKALOID CORE -- 3.1 Overview -- 3.2 Racemic Syntheses -- 3.2.1 C4-C13 Ring Closure a -- 3.2.1.1 Tietze's Formal Synthesis (1997) -- 3.2.1.2 Suga and Yoshida's Formal Synthesis (2002, 2006) -- 3.2.1.3 Stoltz's Formal Synthesis (2007) -- 3.2.1.4 Huang's Formal Synthesis (2013) -- 3.2.1.5 Huang and Wang's Formal Synthesis (2015) -- 3.2.1.6 Nagasaka's Formal Synthesis (2002) -- 3.2.1.7 Li's Formal Synthesis (2007) -- 3.2.1.8 Yang and Liu's Formal Synthesis (2009) -- 3.2.1.9 Zhang and Liu's Formal Synthesis (2013) -- 3.2.1.10 Bubnov's Formal Synthesis (2008) -- 3.2.2 N9-C5 Ring Closure c -- 3.2.2.1 Li's Formal Syntheses (2003-2005) -- 3.2.2.2 Tu and Zhang's Formal Synthesis (2009) -- 3.2.2.3 Li's Formal Synthesis (2011) -- 3.2.2.4 Jiang's Formal Synthesis (2013) -- 3.2.3 Other Strategies for Ring B Formation -- 3.2.3.1 C4-C5 Ring Closure b: Hong's Formal Synthesis (2015) -- 3.2.3.2 N9-C10 Ring Closure e: Chandrasekhar's Total Synthesis (2016) -- 3.3 Syntheses of Enantioenriched Cephalotaxine -- 3.3.1 Asymmetric Catalysis.

3.3.1.1 Tietze's Formal Synthesis (1999) -- 3.3.1.2 Tu's Formal Synthesis (2012) -- 3.3.1.3 Renaud's Formal Synthesis (2012) -- 3.3.1.4 Trost's Formal Synthesis (2012) -- 3.3.2 Use of Chiral Auxiliaries -- 3.3.2.1 Royer's Total Synthesis (2004) -- 3.3.2.2 Dumas and d'Angelo's Formal Synthesis (2005) -- 3.3.3 Incorporation of Chiral Sources -- 3.3.3.1 Ikeda's Formal Synthesis (1999) -- 3.3.3.2 El Bialy's Formal Synthesis (2002) -- 3.3.3.3 Hayes's Formal Syntheses (2008) -- 3.3.3.4 Djaballah and Gin's Synthesis (2008) -- 3.3.3.5 Ishibashi's Total Synthesis (2008) -- 3.3.4 Chemical Resolutions -- 3.3.4.1 Nagasaka's Formal Synthesis (1997) -- 3.3.4.2 El Bialy's Formal Synthesis -- 3.3.4.3 Stoltz's Formal Syntheses (2007) -- 3.3.5 Enzymatic Resolutions -- 3.3.5.1 Mariano's Formal Syntheses (2006) -- 3.3.5.2 Renaud's Formal Synthesis (2012) -- 4. SYNTHESIS AND COUPLING OF THE SIDE CHAINS OF CEPHALOTAXUS ESTERS -- 4.1 Synthesis of Cephalotaxine Esters -- 4.1.1 Robin's Synthesis of Semisynthetic Homoharringtonine (1999) -- 4.1.2 Marguerit's Synthesis of [14C]-Labeled Homoharringtonine (2015) -- 4.1.3 Gin's Synthesis of Deoxyharringtonine (2006) -- 4.1.4 Djaballah and Gin's Synthesis of Anhydroharringtonine, Homoharringtonine, and Homodeoxyharringtonine (2008) -- 4.2 Synthesis of Side Chains of Cephalotaxus Esters -- 4.2.1 Dumas and d'Angelo's Synthesis (2001) -- 4.2.2 Tietze's Synthesis (2005) -- 4.2.3 Russel's Synthesis (2006) -- 4.2.4 Royer's Synthesis (2009) -- 4.2.5 Yang's Synthesis (2013) -- 4.2.6 Hung's Synthesis (2014) -- 4.2.7 Mac's Synthesis (2016) -- 5. SYNTHETIC ANALOGS AND THEIR BIOLOGICAL PROPERTIES -- 5.1 Cephalotaxine Analogs -- 5.1.1 Tietze's Cephalotaxine Analogs (2000, 2007) -- 5.1.2 Bubnov's Cephalotaxine Analogs (2005-2010) -- 5.1.3 Royer's Cephalotaxine Analogs (2004-2010) -- 5.1.4 Chandrasekhar's Cephalotaxine Analogs (2016).

5.2 Cephalotaxus Esters With Side Chain Analogs -- 5.2.1 Robin's Analogs (2002-2004) -- 5.2.2 Djaballah and Gin's Analogs (2008) -- 5.2.3 Lai's Analogs (2013) -- 6. PHARMACOLOGY AND CLINICAL STUDIES -- 6.1 Cellular Pharmacology -- 6.1.1 Molecular Mechanism of Action of Homoharringtonine -- 6.1.2 Potential Use for the Treatment of Other Tumors -- 6.1.3 Combination With Other Agents -- 6.1.4 Resistance Mechanism for Homoharringtonine -- 6.1.5 Mechanism of Allergic Reaction -- 6.1.6 Other Pharmacological Applications -- 6.2 Clinical Application -- 6.2.1 Approved Clinical Applications -- 6.2.2 Different Clinical Trials for Chronic Myeloid Leukemia -- 6.2.3 Administration, Dosage, Metabolites, and Elimination -- 6.2.4 Combination Therapy -- 6.2.4.1 Combination Therapy for Chronic Myeloid Leukemia -- 6.2.4.2 Combination Therapy for Acute Myeloid Leukemia -- 6.2.5 Other Clinical Applications -- 6.2.6 Side Effects -- 6.3 Natural Extracts From Cephalotaxus sp. and Natural Chinese Medicine -- ACKNOWLEDGMENTS -- REFERENCES -- CUMULATIVE INDEX OF TITLES -- A -- B -- C -- D -- E -- F -- G -- H -- I -- K -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- V -- W -- X -- Y -- INDEX -- A -- B -- C -- D -- E -- F -- G -- H -- I -- L -- M -- N -- O -- P -- R -- S -- T -- V -- X -- Z -- Back Cover.